Skip to main content

GSK vs Sanofi: Strategic Comparison

Direct Answer

Sanofi is the bigger of the two by revenue: it reported ~$49.3 billion (€43.626 billion) in net sales for fiscal 2025 (ended December 31, 2025), equal to roughly $49.5 billion, versus GSK's £32.667 billion, or about $43.3 billion at September 2026 exchange rates, a gap of around 14%. Sanofi was also slightly more profitable on margin, with net income equal to 17.9% of sales against GSK's 17.5%, and it employed 74,846 people versus GSK's 66,800 at the end of 2025. Even so, stock market investors valued both companies at close to $100 billion in late September 2026, about $100 billion for GSK per Pitchbook data and $99.8 billion for Sanofi per StockAnalysis, reflecting concerns about each company's reliance on a small number of products.

GSK and Sanofi are nearly tied in stock market value, both near $100 billion in late September 2026, even though Sanofi's revenue runs about 14% higher. GSK traces back to a 1715 London pharmacy and the 2000 merger of Glaxo Wellcome and SmithKline Beecham, while Sanofi's lineage starts with Elf Aquitaine's 1973 healthcare arm and the 2004 takeover of Aventis. Both companies also just changed chief executives: Luke Miels became GSK's CEO on January 1, 2026, succeeding Emma Walmsley, and Belén Garijo took over at Sanofi after its April 29, 2026 annual meeting, succeeding Paul Hudson. For fiscal 2025 (year ended December 31, 2025), GSK reported ~$43.1 billion (£32.667 billion) of turnover and ~$7.55 billion (£5.716 billion) of profit attributable to shareholders with about 66,800 employees, while Sanofi reported ~$49.3 billion (€43.626 billion) of net sales and ~$8.83 billion (€7.813 billion) of net income with 74,846 employees.

Editorial research by Swet Parvadiya. Figures keep each company's fiscal year; amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Sources are listed below.

Share

Key Differences at a Glance

FieldGSK plcSanofi S.A.
Latest annual revenue~$43.1B (FY2025)~$49.3B (FY2025)
Founded17152004
Employees66,80074,846
Market Cap$100.0B$100.0B
HeadquartersUnited KingdomFrance
Revenue / Employee$646k / employee$659k / employee
Valuation Multiple2.3x P/S2.0x P/S

Strategic Positioning

Business model and competitive context from the cited profiles

GSK plc Strategic Vector

FY2025 Revenue Baseline

GSK plc's long-term commercial strategy prioritizes scaling high-margin growth vectors while actively mitigating structural industry risks. In terms of growth initiatives, management is allocating capital toward oncology and liver disease, where nuvalent's lung-cancer drugs, efimosfermin for steatotic liver disease and bepirovirsen for hepatitis B could add new revenue streams, supporting the target of more than $52. Concurrently, the organization focuses on navigating market pressures around us pricing and vaccine policy, addressing environments where uS drug-pricing reforms, tariffs and changes to vaccine recommendations can quickly reduce demand, as shown by the Arexvy slowdown in 2024-2025. By maintaining disciplined capital allocation and operational rigor, GSK plc aims to protect its unit economics and preserve its economic moat across changing market cycles.

Productivity: $646k / employee

Sanofi S.A. Strategic Vector

FY2025 Revenue Baseline

Sanofi's 2025-2026 numbers show a company growing fast on Dupixent while trying to prove its pipeline can carry growth after the antibody's exclusivity ends; the Q2 2026 program cuts suggest the new CEO prefers fewer, better-funded bets plus outside deals.

Productivity: $659k / employee
Comparative Divergence: GSK and Sanofi compete directly across several vaccine categories: GSK's Bexsero, Menveo and the newly approved five-in-one Penmenvy go up against Sanofi's MenQuadfi in meningitis, and GSK's Arexvy competes in the broader RSV field where Sanofi also plays through its infant antibody Beyfortus, partnered with AstraZeneca. In immunology, outside analysis has rated Sanofi's position as stronger, one 2025 competitor review of GSK specifically flagged it as weaker in immunology than Sanofi, AstraZeneca, Roche and AbbVie, since GSK's comparable biologics Nucala and Exdensur remain far smaller than Dupixent. Both boards also replaced long-serving chief executives within months of each other in 2026, Sanofi's board ended Paul Hudson's run in February and installed Belén Garijo in April, while GSK's Luke Miels took over from Emma Walmsley on January 1, leaving both companies simultaneously explaining new strategic priorities to investors through 2026.

GSK vs Sanofi Market Share

GSK plc market share
GSK plc is one of the premier market leaders in Pharmaceuticals & Biotechnology, commanding substantial market share and strong brand equity across its core geographic operating regions.
Sanofi S.A. market share
Sanofi was one of the world's 15 largest pharmaceutical companies by sales in 2025. Dupixent is the leading biologic in type 2 inflammatory diseases, and Sanofi is among the largest suppliers of influenza vaccines.

Quick Stats Comparison

MetricGSK plcSanofi S.A.
Revenue~$43.1B (FY2025)~$49.3B (FY2025)
Founded17152004
HeadquartersLondon, United KingdomParis, France
Market Cap$100.0B$100.0B
Employees66,80074,846
Revenue / Employee$646k / employee$659k / employee
Valuation Multiple2.3x P/S2.0x P/S

GSK Revenue vs Sanofi Revenue — Year by Year

YearGSK plcSanofi S.A.Higher reported revenue
2025~$43.1B~$49.3BSanofi S.A. (approx. USD)
2024~$41.4B~$46.4BSanofi S.A. (approx. USD)
2023~$40B~$42.7BSanofi S.A. (approx. USD)
2022~$38.7B~$45.5BSanofi S.A. (approx. USD)
2021~$32.6B~$44.3BSanofi S.A. (approx. USD)

Business Model Breakdown

Overview: GSK plc vs Sanofi S.A.

This in-depth comparison examines GSK plc and Sanofi S.A. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching GSK plc on its own, evaluating Sanofi S.A., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between GSK plc and Sanofi S.A. is widest.

On the headline numbers, annual revenue is ~$43.1B (FY2025) for GSK plc and ~$49.3B (FY2025) for Sanofi S.A., while their respective market capitalizations stand at $100.0B and $100.0B. GSK plc is headquartered in United Kingdom and Sanofi S.A. in France, and those different home markets shape how each company competes.

GSK plc: GSK plc is listed in London (LSE: GSK) and New York (NYSE: GSK) and is a FTSE 100 constituent. It operates in about 70 countries with 33 manufacturing sites and about 66,800 employees. The company focuses on four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. Well-known products include Shingrix, Arexvy, Trelegy Ellipta, Ventolin, Nucala, Dovato and Cabenuva. The company is headquartered in London, United Kingdom.

Sanofi S.A.: Sanofi S.A. is headquartered in Paris and listed on Euronext Paris (SAN) and Nasdaq (SNY ADRs). It employed 74,846 people at the end of 2025. The company sells Dupixent with Regeneron, the infant RSV antibody Beyfortus with AstraZeneca, a large influenza and pediatric vaccine portfolio, rare disease enzyme therapies from Genzyme, and older medicines such as Lantus, Toujeo, Plavix and Lovenox. The company is headquartered in Paris, France.

Business Models: How GSK plc and Sanofi S.A. Make Money

GSK plc and Sanofi S.A. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between GSK plc and Sanofi S.A..

GSK plc business model: GSK makes money by discovering, manufacturing and selling prescription medicines and vaccines, mostly to health systems, insurers, pharmacies and governments. Its sales are reported in three groups. Specialty Medicines (~$17.8 billion (£13.5 billion) in 2025, about 41% of sales) covers HIV through ViiV Healthcare, respiratory and immunology biologics such as Nucala and Exdensur, and oncology drugs such as Jemperli, Ojjaara and Blenrep. Vaccines (~$12.1 billion (£9.2 billion), about 28%) are led by Shingrix for shingles, the Bexsero and Menveo meningitis vaccines and the Arexvy RSV vaccine. General Medicines (~$13.2 billion (£10.0 billion), about 31%) includes established inhalers such as Trelegy and Ventolin and antibiotics like Augmentin. GSK also earns royalty income on licensed products.

Sanofi S.A. business model: Sanofi makes money by developing, manufacturing and selling prescription medicines and vaccines to hospitals, pharmacies, wholesalers, insurers and government health systems. In 2025 its ~$49.3 billion (EUR43.6 billion) of net sales broke down into Dupixent (~$17.7 billion (EUR15.7 billion)), pharma launches such as ALTUVIIIO and Ayvakit (~$4.41 billion (EUR3.9 billion)), vaccines (~$8.93 billion (EUR7.9 billion)) and other established medicines (~$18.2 billion (EUR16.1 billion)). The United States generated ~$25.1 billion (EUR22.2 billion) and Europe ~$10.4 billion (EUR9.2 billion). Dupixent profits are shared with Regeneron under their long-running antibody collaboration.

Competitive Advantage: GSK plc vs Sanofi S.A.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of GSK plc stack up against those of Sanofi S.A..

GSK plc competitive advantage: GSK's advantages are scale in vaccine manufacturing, a long-acting HIV portfolio through ViiV Healthcare, and the AS01 adjuvant system used in Shingrix and Arexvy. Vaccines are hard to copy because they depend on biological manufacturing, cold-chain distribution and long-term government contracts. ViiV's long-acting injectables, Cabenuva for treatment and Apretude for prevention, aim to move patients onto newer regimens ahead of the dolutegravir patent expiry.

Sanofi S.A. competitive advantage: Sanofi's edge rests on two assets that are hard to copy. Dupixent is approved across a long list of type 2 inflammatory diseases, from atopic dermatitis and asthma to COPD and chronic spontaneous urticaria, which gives it unusual breadth for a single antibody. Its vaccines business, built on the former Sanofi Pasteur, runs large-scale influenza and pediatric vaccine manufacturing that few rivals can match, and it adds rare disease know-how inherited from Genzyme.

Growth Strategy: Where GSK plc and Sanofi S.A. Are Headed

Future prospects matter as much as current results. The growth strategies below explain how GSK plc and Sanofi S.A. each plan to expand from here.

GSK plc growth strategy: Under Luke Miels, GSK is combining targeted acquisitions with faster R&D. Deals since 2025 include IDRx (GIST, January 2025), efimosfermin from Boston Pharmaceuticals ($1.2 billion upfront, July 2025) and Nuvalent ($10.6 billion, completed July 2026). In July 2026 GSK identified 7 assets across 18 indications in oncology, respiratory, hepatology and vaccines to speed up, raised its 2026 phase III start target from 10 to more than 20, and launched a cost programme to fund that investment.

Sanofi S.A. growth strategy: Sanofi's strategy, set under Paul Hudson's 2019 'Play to Win' plan and now being tightened by Belén Garijo, is to concentrate on immunology, rare diseases, neurology and vaccines. Key steps were exiting most diabetes and cardiovascular research, separating consumer health (Opella, majority sold to CD&R in April 2025) and buying specialty assets such as Provention Bio (2023), Inhibrx's AATD drug (2024) and Blueprint Medicines (2025). Garijo has stressed execution discipline and capital allocation, and in Q2 2026 she discontinued several late-stage programs.

Financial Picture: GSK plc vs Sanofi S.A.

A closer look at the financial trajectory of GSK plc and Sanofi S.A. rounds out the comparison.

GSK plc: GSK reported 2025 turnover of ~$43.2 billion (£32.7 billion) (+4% at actual rates, +7% at constant currency), operating profit of ~$10.4 billion (£7.9 billion), profit attributable to shareholders of ~$7.52 billion (£5.7 billion), and earnings per share of 141.1p. Cash generated from operations was ~$11.7 billion (£8.9 billion) and free cash flow ~$5.28 billion (£4.0 billion). In Q2 2026, sales rose 5% to ~$11.1 billion (£8.4 billion) and core operating profit rose 7% to ~$3.7 billion (£2.8 billion), beating consensus, while reported operating profit fell to ~$635 million (£481 million) because of the camlipixant impairment. H1 2026 turnover was ~$21.1 billion (£16.0 billion). GSK reaffirmed 2026 guidance of 3% to 5% turnover growth and 7% to 9% core operating profit growth, expects a 70p dividend for 2026, and launched a three-year plan targeting ~$2.51 billion (£1.9 billion) of annual savings by 2029. GSK plc is a colossal British multinational pharmaceutical and biotechnology company, commanding a market valuation typically exceeding $70 billion.

Sanofi S.A.: Sanofi's finances now hinge on Dupixent. Sales of the antibody reached ~$17.7 billion (EUR15.7 billion) in 2025 and ~$5.88 billion (EUR5.2 billion) in Q2 2026 alone, up 37.6%, and management has targeted around $24.9 billion (EUR22 billion) by 2030. Group net sales grew from ~$46.4 billion (EUR41.081 billion) in 2024 to ~$49.3 billion (EUR43.626 billion) in 2025, free cash flow was about $9.15 billion (EUR8.1 billion), and Q2 2026 business EPS rose 33.3% at CER to EUR2.09. The 2025 Opella deal turned the consumer business into a 48.2% equity stake and brought in cash that Sanofi used for acquisitions such as Blueprint Medicines and share buybacks. Sanofi is a colossal French multinational pharmaceutical and healthcare company, commanding a massive market valuation generally exceeding $130 billion.

Company-Specific SWOT Notes

GSK plc

Strength

Vaccines generated ~$12.1 billion (£9.2 billion) in 2025, led by Shingrix (~$4.75 billion (£3.6 billion)) and meningitis vaccines (~$2.11 billion (£1.6 billion)), backed by large biological manufacturing capacity and the AS01 adjuvant system.

Strength

Specialty Medicines grew 17% to ~$17.8 billion (£13.5 billion) in 2025 and 14% in Q2 2026, with oncology up 43% in 2025.

Weakness

HIV sales of ~$10.2 billion (£7.7 billion) rely heavily on dolutegravir-based regimens, which lose exclusivity between 2028 and 2030.

Weakness

The 2026 decision to stop camlipixant, acquired with Bellus Health in 2023, led to about $1.72 billion (£1.3 billion) of impairments in Q2 2026.

Opportunity

Nuvalent's lung-cancer drugs, efimosfermin for steatotic liver disease and bepirovirsen for hepatitis B could add new revenue streams, supporting the target of more than $52.8 billion (£40 billion) in sales by 2031.

Threat

US drug-pricing reforms, tariffs and changes to vaccine recommendations can quickly reduce demand, as shown by the Arexvy slowdown in 2024-2025.

Sanofi S.A.

Strength

Dupixent sales reached ~$17.7B (EUR15.7B) in 2025 and ~$5.88B (EUR5.2B) in Q2 2026 across many type 2 inflammatory diseases.

Strength

Dupixent (dupilumab) generates billions in high-margin revenues as the foundational standard-of-care biologic across atopic dermatitis, asthma, and chronic obstructive pulmonary disease (COPD).

Weakness

Roughly a third of sales depends on one product shared with Regeneron.

Weakness

A substantial portion of pharmaceutical operating earnings is concentrated in Dupixent, requiring accelerated clinical development across oncology and neurology to diversify long-term earnings.

Opportunity

Strong cash generation and the Opella proceeds give room for acquisitions like Blueprint Medicines.

Threat

2026 late-stage discontinuations, US price negotiation and eventual Dupixent biosimilars could slow growth.

Factual Scorecard

CategoryResultWhy
Same-period Revenue ScaleSanofi S.A.~$43.1B (FY2025) versus ~$49.3B (FY2025); the higher figure is identified after approximate USD conversion.
Founded EarlierGSK plcGSK plc was founded in 1715; Sanofi S.A. was founded in 2004.
Verdict

Comparison Takeaway: GSK vs Sanofi

The two companies make money in different shapes. Sanofi is far more concentrated: its antibody Dupixent, co-marketed with Regeneron, generated ~$17.7 billion (€15.7 billion) in 2025, 36% of total sales, and grew 37.6% to ~$5.88 billion (€5.2 billion) in Q2 2026 alone. GSK spreads its revenue more evenly across HIV medicines (~$10.2 billion (£7.7 billion)), vaccines led by Shingrix (~$4.75 billion (£3.6 billion)) and older respiratory drugs like Trelegy (~$3.96 billion (£3.0 billion)), with no single product above 24% of sales. That concentration cuts both ways on growth: Sanofi's Q2 2026 sales rose 17.8% at constant exchange rates to ~$13.1 billion (€11.6 billion), more than three times GSK's 5% constant-currency growth to ~$11.1 billion (£8.4 billion) in the same quarter, but Sanofi's future depends heavily on Dupixent holding up once biosimilar competition eventually arrives. Both companies made similar-sized bets on oncology in 2025-2026, GSK closed its $10.6 billion purchase of Nuvalent in July 2026 and Sanofi closed its roughly $9.1 billion purchase of Blueprint Medicines in July 2025, but GSK is racing against a harder deadline, since its dolutegravir HIV franchise starts losing patent protection in 2028.

Methodology and sourcing reviewed by Swet Parvadiya. No date is shown unless this comparison has its own editorial review date.

Frequently Asked Questions: GSK vs Sanofi

Is GSK or Sanofi bigger by revenue?

Sanofi is bigger. It reported ~$49.3 billion (€43.626 billion) in net sales for fiscal 2025 (ended December 31, 2025), about $49.5 billion, versus GSK's £32.667 billion, about $43.3 billion at September 2026 exchange rates, roughly 14% more than GSK.

Which is more profitable, GSK or Sanofi?

Sanofi has the higher net margin, 17.9% in fiscal 2025 (~$8.83 billion (€7.813 billion) of net income on ~$49.3 billion (€43.626 billion) of sales) versus GSK's 17.5% (~$7.55 billion (£5.716 billion) of profit on ~$43.1 billion (£32.667 billion) of turnover), though the gap is narrow.

Who are the CEOs of GSK and Sanofi?

Luke Miels has led GSK since January 1, 2026, succeeding Emma Walmsley. Belén Garijo has led Sanofi since the company's April 29, 2026 annual meeting, succeeding Paul Hudson, whose mandate the board ended in February 2026.

Does GSK or Sanofi lead in vaccines?

Both are major vaccine makers but in different niches: GSK leads in shingles with Shingrix (~$4.75 billion (£3.6 billion) in 2025) and meningitis with Bexsero, Menveo and Penmenvy, while Sanofi leads in influenza with Fluzone and Vaxigrip and markets the infant RSV antibody Beyfortus with AstraZeneca.

Which is the better stock, GSK or Sanofi?

Neither is clearly better: Sanofi grew sales 17.8% at constant currency in Q2 2026 versus GSK's 5%, mainly on Dupixent, but GSK is less dependent on one drug, and both were valued at roughly $100 billion by the stock market in late September 2026.

Which company was founded first, GSK plc or Sanofi S.A.?

GSK plc was founded in 1715; Sanofi S.A. was founded in 2004.

What revenue did GSK plc and Sanofi S.A. report?

GSK plc had ~$43.1B (FY2025), while Sanofi S.A. had ~$49.3B (FY2025). These figures describe revenue scale; they do not by themselves determine an overall winner.

How do GSK plc and Sanofi S.A. make money?

GSK plc: GSK makes money by discovering, manufacturing and selling prescription medicines and vaccines, mostly to health systems, insurers, pharmacies and governments. Sanofi S.A.: Sanofi makes money by developing, manufacturing and selling prescription medicines and vaccines to hospitals, pharmacies, wholesalers, insurers and government health systems.

Which is better, GSK plc or Sanofi S.A.?

There is no evidence-based single winner. Compare GSK plc and Sanofi S.A. on the same fiscal period and the metric relevant to the question, such as revenue, profitability, growth, product fit, or market value.

Sources & References

Quick Answer

Sanofi is the bigger of the two by revenue: it reported ~$49.3 billion (€43.626 billion) in net sales for fiscal 2025 (ended December 31, 2025), equal to roughly $49.5 billion, versus GSK's £32.667 billion, or about $43.3 billion at September 2026 exchange rates, a gap of around 14%. Sanofi was also slightly more profitable on margin, with net income equal to 17.9% of sales against GSK's 17.5%, and it employed 74,846 people versus GSK's 66,800 at the end of 2025. Even so, stock market investors valued both companies at close to $100 billion in late September 2026, about $100 billion for GSK per Pitchbook data and $99.8 billion for Sanofi per StockAnalysis, reflecting concerns about each company's reliance on a small number of products.

Verdict

The two companies make money in different shapes. Sanofi is far more concentrated: its antibody Dupixent, co-marketed with Regeneron, generated ~$17.7 billion (€15.7 billion) in 2025, 36% of total sales, and grew 37.6% to ~$5.88 billion (€5.2 billion) in Q2 2026 alone. GSK spreads its revenue more evenly across HIV medicines (~$10.2 billion (£7.7 billion)), vaccines led by Shingrix (~$4.75 billion (£3.6 billion)) and older respiratory drugs like Trelegy (~$3.96 billion (£3.0 billion)), with no single product above 24% of sales. That concentration cuts both ways on growth: Sanofi's Q2 2026 sales rose 17.8% at constant exchange rates to ~$13.1 billion (€11.6 billion), more than three times GSK's 5% constant-currency growth to ~$11.1 billion (£8.4 billion) in the same quarter, but Sanofi's future depends heavily on Dupixent holding up once biosimilar competition eventually arrives. Both companies made similar-sized bets on oncology in 2025-2026, GSK closed its $10.6 billion purchase of Nuvalent in July 2026 and Sanofi closed its roughly $9.1 billion purchase of Blueprint Medicines in July 2025, but GSK is racing against a harder deadline, since its dolutegravir HIV franchise starts losing patent protection in 2028.

Cite This Page

Automatically generated citations for researchers.

APA Format

CorpDigest. (2026). GSK plc vs Sanofi S.A. Comparison. from https://corpdigest.com/compare/gsk-vs-sanofi

MLA Format

CorpDigest. "GSK plc vs Sanofi S.A. Comparison." CorpDigest, 2026, https://corpdigest.com/compare/gsk-vs-sanofi.

Chicago Format

CorpDigest. "GSK plc vs Sanofi S.A. Comparison." CorpDigest. 2026. https://corpdigest.com/compare/gsk-vs-sanofi.

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.